newsfilter
← Latest News
Business Wire·

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

  • Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) will release third-quarter 2026 financial results & business highlights before the U.S. market open on Thursday, November 5, 2026.
  • Management will host a conference call & audio webcast at 8:30 a.m. ET on November 5, 2026, to discuss operational results.
  • Interested parties may pre-register via the "Events" section of the Investor Relations website or the provided link, with registration recommended 15 minutes prior to the event.
  • The webcast, replay, & related information are accessible at https://xerispharma.com/investor-relations.
  • The company currently markets three products: Recorlev® for endogenous Cushing's syndrome, Gvoke® for severe hypoglycemia, & Keveyis® for primary periodic paralysis.
  • Xeris' development pipeline includes XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism, & early-stage programs utilizing XeriSol® & XeriJect® technology platforms.
  • Xeris Biopharma Holdings is headquartered in Chicago, IL.
  • Investor & media inquiries should be directed to Vice President of Investor Relations Cristi Barnett at ir@xerispharma.com.